NO20031671L - Dioksolananaloger for forbedret intercellulaer avlevering - Google Patents
Dioksolananaloger for forbedret intercellulaer avleveringInfo
- Publication number
- NO20031671L NO20031671L NO20031671A NO20031671A NO20031671L NO 20031671 L NO20031671 L NO 20031671L NO 20031671 A NO20031671 A NO 20031671A NO 20031671 A NO20031671 A NO 20031671A NO 20031671 L NO20031671 L NO 20031671L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- alkenyl
- aryl
- case
- aromatic ring
- Prior art date
Links
- 150000002012 dioxanes Chemical class 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000006574 non-aromatic ring group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Forbindelser som har den følgende formel (I). hvor Ri er f.eks. H, C_-alkyl, C--alkenyl, C--aryl, C.-heteroaromatisk ring eller C_-ikke-aromatisk ring; Rog Rer f.eks. i hvert tilfelle uavhengig av hverandre H, C--alkyl, C--alkenyl, C--aryl, C_-heteroaromatisk ring eller C.-ikke-aromatisk ring; eller et aminosyreradikal eller en. dipeptid- eller tripeptidkjede eller etterligning derav, hvor aminosyreradikalene er valgt fra gruppen som omfatter Glu, Gly, Ala, Val, Leu, Ile, Pro, Phe, Tyr, Trp, Ser, Thr, Cys, Met, Asn og Gin, og som i hvert tilfelle eventuelt er avsluttet med -R.; Rer i hvert tilfelle H, C.-alkyl, C.-alkenyl, C.-alkyl-C.-aryl, Co-o-alkyl-C_-heteroaromatisk ring, C.-ikkearomatisk ring som eventuelt inneholder 1-3. heteroatomer valgt fra gruppen som omfatter 0, N og S; og R7 er i hvert tilfelle C_-alkyl, C--alkenyl, Ce-io-aryl, C.-heteroaromatisk ring, C.-ikke-aromatisk ring som eventuelt inneholder 1-3 heteroatomer valgt fra gruppen som omfatter 0, N og S, -C(0)R, -C(0)OR; og X og Y er uavhengig av hverandre Br, Cl, I, F, OH, 0Reller NRR, og minst én av X og Y er NRR; eller et farmasøytisk akseptabelt salt derav, kan anvendes ved behandling av en pasient som har kreft.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23988500P | 2000-10-13 | 2000-10-13 | |
| US28842401P | 2001-05-04 | 2001-05-04 | |
| PCT/CA2001/001464 WO2002030922A2 (en) | 2000-10-13 | 2001-10-15 | Dioxolane analogs for improved inter-cellular delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20031671D0 NO20031671D0 (no) | 2003-04-11 |
| NO20031671L true NO20031671L (no) | 2003-06-13 |
Family
ID=26932965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20031671A NO20031671L (no) | 2000-10-13 | 2003-04-11 | Dioksolananaloger for forbedret intercellulaer avlevering |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20030013660A1 (no) |
| EP (1) | EP1324997A2 (no) |
| JP (1) | JP2004510832A (no) |
| KR (1) | KR20030096226A (no) |
| CN (1) | CN100376570C (no) |
| AU (2) | AU1201502A (no) |
| CA (1) | CA2425359A1 (no) |
| HU (1) | HUP0301363A2 (no) |
| MX (1) | MXPA03003278A (no) |
| NO (1) | NO20031671L (no) |
| NZ (1) | NZ537432A (no) |
| PL (1) | PL361310A1 (no) |
| WO (1) | WO2002030922A2 (no) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076472A2 (en) | 2001-03-23 | 2002-10-03 | Shire Biochem Inc. | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs |
| KR100978904B1 (ko) | 2001-12-14 | 2010-08-31 | 파마셋 인코포레이티드 | 바이러스 감염 치료용 ｎ4-아실사이토신 뉴클레오사이드 |
| WO2004052369A1 (en) * | 2002-12-06 | 2004-06-24 | Shire Biochem Inc. | Pharmaceutical combinations and methods for the treatment of leukemia |
| GB0306907D0 (en) * | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Boireductively-activated prodrugs |
| WO2005074654A2 (en) * | 2004-02-03 | 2005-08-18 | Emory University | Methods to manufacture 1,3-dioxolane nucleosides |
| NO324263B1 (no) * | 2005-12-08 | 2007-09-17 | Clavis Pharma Asa | Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser |
| CA2662147A1 (en) * | 2006-09-01 | 2008-03-13 | University Of Georgia Research Foundation, Inc. | L-oddc prodrugs for cancer |
| JP5784603B2 (ja) * | 2009-08-07 | 2015-09-24 | ダウ アグロサイエンシィズ エルエルシー | Ｎ１−スルホニル−５−フルオロピリミジノン誘導体 |
| EP2717699B1 (en) * | 2011-06-06 | 2020-06-03 | Veiled Therapeutics LLC | Acid-labile lipophilic prodrugs of chemo-therapeutic anti-cancer agents |
| CN104902757B (zh) | 2012-12-28 | 2019-01-08 | 阿达玛马克西姆股份有限公司 | N-(取代的)-5-氟-4-亚氨基-3-甲基-2-氧代-3,4-二氢嘧啶-1(2h)-羧酸酯衍生物 |
| JP6258969B2 (ja) | 2012-12-28 | 2018-01-10 | アダマ・マクテシム・リミテッド | Ｎ−（置換）−５−フルオロ−４−イミノ−３−メチル−２−オキソ−３，４−ジヒドロピリミジン−１（２ｈ）−カルボキサミド誘導体 |
| CN112094262A (zh) | 2012-12-31 | 2020-12-18 | 阿达玛马克西姆股份有限公司 | 作为杀真菌剂的化合物 |
| CR20160344A (es) | 2013-12-31 | 2016-12-19 | Adama Makhteshim Ltd | Mezclas fungicidas sinérgicas para el control fúngico en cereales |
| UA129860C2 (uk) | 2013-12-31 | 2025-08-27 | Адама Махтешім Лтд. | 5-фтор-4-іміно-3-(алкіл/заміщений алкіл)-1-(арилсульфоніл)-3,4-дигідропіримідин-2(1h)-он і способи його одержання |
| ES2927212T3 (es) * | 2014-08-25 | 2022-11-03 | Medivir Ab | Análogos de dioxano de uridina para el tratamiento de cáncer |
| AU2015346037A1 (en) * | 2014-11-14 | 2017-07-06 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers |
| TWI695841B (zh) | 2015-06-22 | 2020-06-11 | 瑞典商米迪維艾克提伯拉公司 | 治療癌症之前藥 |
| WO2016210190A1 (en) | 2015-06-24 | 2016-12-29 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
| WO2017151044A1 (en) * | 2016-03-02 | 2017-09-08 | Medivir Ab | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
| IL269884B2 (en) | 2017-04-18 | 2023-09-01 | Gemphire Therapeutics Inc | Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350753B1 (en) * | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
| US5270315A (en) * | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
| NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
| US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| DK1165096T3 (da) * | 1999-03-29 | 2010-01-25 | Shire Canada Inc | Anvendelse af cytidinderivater til behandling af leukæmi |
| EP1265890B1 (en) * | 2000-02-11 | 2007-04-18 | Shire BioChem Inc. | Stereoselective synthesis of nucleoside analogues |
-
2001
- 2001-10-15 AU AU1201502A patent/AU1201502A/xx active Pending
- 2001-10-15 PL PL01361310A patent/PL361310A1/xx not_active Application Discontinuation
- 2001-10-15 WO PCT/CA2001/001464 patent/WO2002030922A2/en not_active Ceased
- 2001-10-15 US US09/976,249 patent/US20030013660A1/en not_active Abandoned
- 2001-10-15 EP EP01980081A patent/EP1324997A2/en not_active Withdrawn
- 2001-10-15 NZ NZ537432A patent/NZ537432A/en unknown
- 2001-10-15 MX MXPA03003278A patent/MXPA03003278A/es active IP Right Grant
- 2001-10-15 CN CNB018173659A patent/CN100376570C/zh not_active Expired - Lifetime
- 2001-10-15 KR KR10-2003-7005114A patent/KR20030096226A/ko not_active Withdrawn
- 2001-10-15 CA CA002425359A patent/CA2425359A1/en not_active Abandoned
- 2001-10-15 HU HU0301363A patent/HUP0301363A2/hu unknown
- 2001-10-15 JP JP2002534308A patent/JP2004510832A/ja active Pending
- 2001-10-15 AU AU2002212015A patent/AU2002212015B2/en not_active Ceased
-
2003
- 2003-04-11 NO NO20031671A patent/NO20031671L/no unknown
-
2005
- 2005-06-10 US US11/149,193 patent/US20050256034A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1324997A2 (en) | 2003-07-09 |
| NO20031671D0 (no) | 2003-04-11 |
| US20030013660A1 (en) | 2003-01-16 |
| CA2425359A1 (en) | 2002-04-18 |
| WO2002030922A3 (en) | 2002-09-26 |
| NZ537432A (en) | 2005-05-27 |
| JP2004510832A (ja) | 2004-04-08 |
| CN1471526A (zh) | 2004-01-28 |
| WO2002030922A2 (en) | 2002-04-18 |
| KR20030096226A (ko) | 2003-12-24 |
| AU1201502A (en) | 2002-04-22 |
| PL361310A1 (en) | 2004-10-04 |
| HUP0301363A2 (hu) | 2005-12-28 |
| CN100376570C (zh) | 2008-03-26 |
| MXPA03003278A (es) | 2005-07-01 |
| AU2002212015B2 (en) | 2007-01-25 |
| US20050256034A1 (en) | 2005-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20031671L (no) | Dioksolananaloger for forbedret intercellulaer avlevering | |
| BG93979A (bg) | Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им | |
| NO911854L (no) | Fremgangsmaate for fremstilling av peptid-derivater. | |
| HUP0103511A2 (hu) | Oxazolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
| DE60124085D1 (de) | Pde-v hemmer zur behandlung von morbus parkinson | |
| MY135057A (en) | Dolastatin 15 derivatives | |
| NO980195L (no) | Cyklosporinderivater med anti-HIV-effekt | |
| BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
| EA200000723A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| KR910006324A (ko) | 펩티다아제 및 아이소머라제 억제제 | |
| HUP0300684A2 (hu) | Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| TR200302242T2 (tr) | Protein kinaz önleyicileri olarak pirolopirimidinler | |
| DE69533174D1 (de) | Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten | |
| RU2003101319A (ru) | Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты | |
| MXPA05013587A (es) | Agentes terapeuticos utiles para el tratamiento del dolor. | |
| NO157935C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive polypeptider. | |
| CY1107990T1 (el) | Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων | |
| TR200400526T4 (tr) | Göz kurumasının tedavisi için lipoksin A4 ve analogları | |
| AU6999796A (en) | Heterocyclic compounds as bradykinin antagonists | |
| BG106155A (en) | Novel derivatives and analogues of galanthamin | |
| BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| FI94354C (fi) | Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi | |
| DE602004006379D1 (de) | Benzthiazol-3 oxide zur behandlung von proliferativen störungen | |
| NO941151L (no) | Lineære adhesjonsinhibitorer | |
| DE59306654D1 (de) | Cyclopeptide |